USTR Takes Aim At Colombia Over Drug Pricing Policy

 
• By Francesca Bruce

Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.

Colombia
USTR Fixes Colombia In Its Sights

More from Generics

More from Biosimilars & Generics